Latest BioLineRx News & Updates

See the latest news and media coverage for BioLineRx. We track all announcements, press releases, and industry mentions in real time, all in one place.

BioLineRx

Biopharmaceutical company focused on oncology and rare diseases

biolinerx.com

Headquarters: Modi'in, Israel
Founded year: 2003
Company type: Public company
Number of employees: 40–50

Last updated Today

Latest news about BioLineRx

In short: BioLineRx progressed its oncology pipeline by initiating a Phase 1/2a trial for GLIX1 and reported a Q1 2026 earnings beat with a stable cash runway.

Company announcements

May 28 BioLineRx

BioLineRx reports Q1 2026 financial results and corporate update

First patient dosed in Phase 1/2a GLIX1 trial; new preclinical data showed tumor inhibition; cash runway into H1 2027.

May 20 BioLineRx

BioLineRx to report first quarter 2026 results on May 27

Management will hold a conference call at 8:30 a.m. EDT. The release will be before U.S. markets open.

April 28 BioLineRx

BioLineRx and Hemispherian dose first patient in GLIX1 study

The Phase 1/2a trial is for recurrent glioblastoma, with data expected in H1 2027.

March 24 BioLineRx

BioLineRx reports 2025 financial results and corporate update

The company expects to initiate a Phase 1/2a GLIX1 trial in glioblastoma by March end, maintains cash runway into H1 2027, and reported a net loss of $2.0 million.

Media coverage

May 28 The Market is Open

BioLineRx Delivers Strong Q1 2026 Performance, Initiates Pivotal GLIX1 Trial for Glioblastoma

Jerusalem, Israel - May 27, 2026 BioLineRx, a leading developer of novel therapeutic solutions for major unmet medical needs, reported strong financial results for the...

May 27 Stock Observer

BioLineRx (NASDAQ:BLRX) Releases Quarterly Earnings Results, Beats Estimates By $0.68 EPS - Stock Observer

BioLineRx (NASDAQ:BLRX – Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.36) earnings per share for the quarter, beating...

May 17 Yahoo Finance

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company...

April 27 TipRanks

BioLineRx Kicks Off GLIX1 Clinical Trial as Q1 2026 Loss Widens on Higher R&D Spend - TipRanks.com

An update from Bioline RX Ltd Sponsored ADR ( ($BLRX) ) is now available. BioLineRx Ltd. reported unaudited first-quarter 2026 results on May 27, 2026...

Never miss news about BioLineRx

Track BioLineRx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioLineRx competitors & trending companies

Browse news for competitors to BioLineRx and other trending companies.